Cynthia Aranow

Summary

Affiliation: North Shore University Hospital
Country: USA

Publications

  1. ncbi Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Arthritis Res Ther 11:R143. 2009
  2. ncbi Vitamin D and the immune system
    Cynthia Aranow
    Feinstein Institute for Medical Research, Manhasset, NY 11030, USA
    J Investig Med 59:881-6. 2011
  3. ncbi Lupus nephritis: lessons from murine models
    Anne Davidson
    Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    Nat Rev Rheumatol 6:13-20. 2010

Collaborators

  • Anne Davidson
  • Noa Schwartz
  • Tamar Rubinstein
  • Christopher E Collins
  • Jennifer S Michaelson
  • Meggan Mackay
  • Chaim Putterman
  • Lihe Su
  • Brad H Rovin
  • William Stohl
  • Linda C Burkly
  • Irene Blanco
  • Bernard Hojaili

Detail Information

Publications3

  1. ncbi Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study
    Noa Schwartz
    Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Arthritis Res Ther 11:R143. 2009
    ..Evidence for the importance of TWEAK in the pathogenesis of lupus nephritis (LN) has been recently introduced. Thus, TWEAK levels may serve as an indication of LN presence and activity...
  2. ncbi Vitamin D and the immune system
    Cynthia Aranow
    Feinstein Institute for Medical Research, Manhasset, NY 11030, USA
    J Investig Med 59:881-6. 2011
    ....
  3. ncbi Lupus nephritis: lessons from murine models
    Anne Davidson
    Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
    Nat Rev Rheumatol 6:13-20. 2010
    ..Data from murine models of lupus suggest that we need to consider new paradigms for the management of systemic lupus erythematosus that include earlier immune intervention, long-term maintenance therapies and protection of target organs...